ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selinexor

Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.

Drug pageSelinexor: every studyMany companies study it; this page follows only the 40 they lead. All 163 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 13, 201540 company-led studies, 12 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Karyopharm Therapeuticsits history only317 open or runningphase 3since Oct 13, 2015May 16, 2012Dec 2026phase 3 · NCT04442022
Antengeneits history only40 open or runningphase 2since Apr 30, 2019Apr 30, 2019none ahead
Oncotherapeuticsits history only22 open or runningphase 1since Aug 12, 2020Aug 12, 2020Apr 1, 2027phase 1 · NCT06225310
AbbVieits history only11 open or runningphase 3since Nov 28, 2023Nov 28, 2023Dec 2027phase 3 · NCT06158841
Qilu Pharmaceutical11 open or runningphase 3since Aug 13, 2025Aug 13, 2025Dec 2027phase 3 · NCT07138209
Sarah Cannon Research Instituteits history only11 open or runningphase 2since Mar 1, 2021Mar 1, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Qilu Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2025First study: phase 3 study in RecurrenceFirst studyNCT07138209 · 228 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in RecurrenceNCT07138209

TargetBeta

XPO1 →read by rule
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule

Other programs on XPO1

ProgramCompanyFurthest phaseStudies
TQB3107Sino Biopharmaceuticalphase 11

Studies

The one study Qilu Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07138209Recurrence · China3RecruitingDec 2027228

How it is read

Names in the registry

  • “Selinexor”, 32 entries
  • “Selinexor (combination therapy)”, 3 entries
  • “Selinexor 40 mg”, 2 entries
  • “Selinexor 60 mg”, 2 entries
  • “ATG-010”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.